Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Perspective Therapeutics (CATX) Interest & Investment Income (2016 - 2025)

Perspective Therapeutics' Interest & Investment Income history spans 15 years, with the latest figure at $2.6 million for Q4 2024.

  • For Q4 2024, Interest & Investment Income rose 4169.35% year-over-year to $2.6 million; the TTM value through Dec 2024 reached $10.5 million, up 1025.8%, while the annual FY2024 figure was $10.5 million, 1025.8% up from the prior year.
  • Interest & Investment Income for Q4 2024 was $2.6 million at Perspective Therapeutics, down from $3.6 million in the prior quarter.
  • Across five years, Interest & Investment Income topped out at $3.6 million in Q3 2024 and bottomed at $1000.0 in Q2 2020.
  • The 5-year median for Interest & Investment Income is $59500.0 (2022), against an average of $618050.0.
  • The largest annual shift saw Interest & Investment Income plummeted 97.96% in 2020 before it soared 4169.35% in 2024.
  • A 5-year view of Interest & Investment Income shows it stood at $5000.0 in 2020, then soared by 520.0% to $31000.0 in 2021, then surged by 1709.68% to $561000.0 in 2022, then crashed by 88.95% to $62000.0 in 2023, then skyrocketed by 4169.35% to $2.6 million in 2024.
  • Per Business Quant, the three most recent readings for CATX's Interest & Investment Income are $2.6 million (Q4 2024), $3.6 million (Q3 2024), and $3.1 million (Q2 2024).